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DIAGNOSTIC EVALUATION OF THE PROSTATIC
  SERUM ACID PHOSPHATASE （PART III）
Masataka TsucmyA， Mikio IToH， Masanobtt FuKAMi，
    Mieko MiyAKAwA and Masuji KuzE
From the DePartment（）f Urology， Kツ0’o C吻Hosカital，ノ砂醐
        （Chief： Dr． M． Ku2e， M． D．）
  A misdiagnosed’ case of carcinoma of the prostate was discussed． lts histology was
benign and the patient was treated as such， neglecting biochernical data and clinical signs．
  The evaluation of diagnostic value of total serum acid phosphatase and prostatic serum
acid phosphatase was done， and it vvTas concluded that they were very significant in diagnosis
of prostatic cancer in our 13 years experience．
  In the treatrnent of prostatic cancer， the female hormone is not aiways effective and has
its limitation． The other endocrine therapies using male hormoエ1e or皿etabQlic hormone














































































































































































































PSAP ： prostatic serum acid phosphatase， AeP： alkaline phosphatase，
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  Paget’s disease
  osteogenesis imperfecta
  osteogenic sarcoma
  osteopetrosis
  rheumatoid arthritis with osteoporosis
Metabolic diseases with bone皿anifestations
  hyperparathyroidism
Visceral cancers with osseous and／or hepatic
  metastases
  carcinoma of breast， adrenal cortex，
   stomach， lung colon
  hypernephroma
  reticulum cell sarcoma
  Hodgkin’s disease
  retrovesical unclassified tumor
Hepato－biliary diseases
  viral hepatitis
  chlorpromazine hepatitis
  extrahepatic biliary obstruction
  cirrhosis
Reticuloendothelial diseases with hepatic
  and／or osseous manifestations
  Gaucher’s diseases
  Niemann－Pick’s disease
  eosinophilic granuloma
Hematopoietic diseases
  undiagnosed blood dysgenesia
  multiple myeloma
Kidney diseases
  chronic glomerulonephritis
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Fig． 13． Staging system used in VACURG























































































































おこなっているが， Soanes et al．（1968）44）1よその・
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